GLAXO Stock Overview
Operates as a biopharma company in Pakistan and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
GlaxoSmithKline Pakistan Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | PK₨137.26 |
| 52 Week High | PK₨141.50 |
| 52 Week Low | PK₨68.00 |
| Beta | 0.36 |
| 1 Month Change | 49.47% |
| 3 Month Change | 75.08% |
| 1 Year Change | 61.44% |
| 3 Year Change | -7.14% |
| 5 Year Change | 33.26% |
| Change since IPO | 356.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| GLAXO | PK Pharmaceuticals | PK Market | |
|---|---|---|---|
| 7D | 3.2% | 1.7% | 2.6% |
| 1Y | 61.4% | 64.1% | 59.5% |
Return vs Industry: GLAXO underperformed the PK Pharmaceuticals industry which returned 64.7% over the past year.
Return vs Market: GLAXO exceeded the PK Market which returned 59.7% over the past year.
Price Volatility
| GLAXO volatility | |
|---|---|
| GLAXO Average Weekly Movement | 6.7% |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in PK Market | 7.8% |
| 10% least volatile stocks in PK Market | 3.3% |
Stable Share Price: GLAXO's share price has been volatile over the past 3 months.
Volatility Over Time: GLAXO's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of PK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 1,700 | Erum Rahim | www.pk.gsk.com |
GlaxoSmithKline Pakistan Limited operates as a biopharma company in Pakistan and internationally. It deals in anti-infective, dermatology, respiratory, analgesics, immunology, oncology, urology, HIV, vaccines, and analgesics therapy areas. The company sells its products under the Augmentin, Velosef, Amoxil, Dermovate, Clobevate, Betnovate, Cutivate, Calpol, Boostrix, Rotarix, Havrix, and Synflorix.
GlaxoSmithKline Pakistan Limited Fundamentals Summary
| GLAXO fundamental statistics | |
|---|---|
| Market cap | PK₨43.26b |
| Earnings (TTM) | PK₨533.95m |
| Revenue (TTM) | PK₨49.66b |
81.9x
P/E Ratio0.9x
P/S RatioIs GLAXO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GLAXO income statement (TTM) | |
|---|---|
| Revenue | PK₨49.66b |
| Cost of Revenue | PK₨46.25b |
| Gross Profit | PK₨3.42b |
| Other Expenses | PK₨2.88b |
| Earnings | PK₨533.95m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.68 |
| Gross Margin | 6.88% |
| Net Profit Margin | 1.08% |
| Debt/Equity Ratio | 2.6% |
How did GLAXO perform over the long term?
See historical performance and comparison